Profile data is unavailable for this security.
About the company
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
- Revenue in INR (TTM)300.85bn
- Net income in INR53.39bn
- Incorporated1984
- Employees26.34k
- LocationDr Reddy's Laboratories Ltd8-2-337, Road No.3 Banjara HillsHYDERABAD 500034IndiaIND
- Phone+91 4 049002900
- Fax+91 4 049002999
- Websitehttps://www.drreddys.com/
Mergers & acquisitions
| Acquired company | DRREDDY:NSI since announced | Transaction value |
|---|---|---|
| Menolabs LLC | 5.27% | 3.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbott India Ltd | 60.66bn | 12.85bn | 576.17bn | 3.81k | 44.85 | 16.36 | 42.47 | 9.50 | 604.57 | 604.57 | 2,854.72 | 1,657.05 | 1.27 | 5.32 | 15.71 | 15,904,690.00 | 26.82 | 20.92 | 36.97 | 28.59 | 45.09 | 44.20 | 21.18 | 17.26 | 1.71 | 131.36 | 0.0169 | 77.06 | 9.35 | 9.72 | 26.52 | 21.68 | 31.08 | 52.32 |
| Alkem Laboratories Ltd | 127.06bn | 21.22bn | 670.13bn | 17.28k | 31.57 | 5.83 | 27.09 | 5.27 | 177.51 | 177.51 | 1,062.75 | 961.22 | 0.7931 | 1.72 | 5.14 | 7,354,390.00 | 13.49 | 11.88 | 18.66 | 17.50 | 63.10 | 59.26 | 17.01 | 13.94 | 1.97 | 12.21 | 0.1104 | 29.82 | 9.21 | 11.48 | 82.47 | 18.75 | -13.30 | 20.11 |
| Aurobindo Pharma Ltd | 302.95bn | 35.82bn | 708.58bn | 8.80k | 19.91 | 2.29 | 13.85 | 2.34 | 61.29 | 61.29 | 518.43 | 531.65 | 0.6585 | 1.27 | 6.04 | 34,437,900.00 | 7.79 | 9.24 | 11.08 | 13.43 | 58.76 | 53.30 | 11.83 | 12.72 | 1.10 | 13.69 | 0.2144 | 8.64 | 16.68 | 8.19 | 64.62 | 6.06 | 17.96 | 12.47 |
| Lupin Ltd | 214.31bn | 26.26bn | 932.01bn | 21.87k | 35.58 | 5.96 | 25.40 | 4.35 | 57.42 | 57.42 | 468.54 | 342.91 | 0.8761 | 1.35 | 4.48 | 9,800,284.00 | 10.84 | 1.43 | 16.64 | 2.22 | 68.60 | 58.52 | 12.37 | 2.04 | 1.22 | 11.88 | 0.1797 | 75.03 | 20.25 | 6.41 | 345.15 | 30.18 | -1.17 | 9.86 |
| Zydus Lifesciences Ltd | 214.84bn | 42.78bn | 949.94bn | 26.24k | 22.26 | 4.35 | 18.45 | 4.42 | 42.41 | 42.66 | 212.94 | 216.89 | 0.7495 | 1.75 | 5.01 | 8,187,310.00 | 15.00 | 9.05 | 19.96 | 14.01 | 71.43 | 61.15 | 20.01 | 14.33 | 1.58 | 217.94 | 0.0078 | 16.48 | 13.40 | 8.23 | 95.25 | 15.72 | -3.03 | -3.04 |
| Dr Reddy's Laboratories Ltd | 300.85bn | 53.39bn | 995.78bn | 26.34k | 18.67 | 3.24 | 14.34 | 3.31 | 64.03 | 64.03 | 360.85 | 369.12 | 0.7379 | 1.37 | 3.90 | 11,420,450.00 | 13.31 | 11.37 | 18.14 | 16.02 | 70.69 | 65.86 | 18.03 | 14.63 | 1.36 | 30.69 | 0.1349 | 15.91 | 13.54 | 12.64 | 23.75 | 23.39 | 26.78 | 14.87 |
| Mankind Pharma Ltd | 110.18bn | 21.15bn | 1.03tn | 19.54k | 48.55 | 9.70 | 39.95 | 9.30 | 52.70 | 52.70 | 274.57 | 263.69 | 0.8786 | 2.02 | 9.46 | 5,638,684.00 | 17.05 | -- | 21.79 | -- | 70.48 | -- | 19.41 | -- | 2.37 | 99.72 | 0.0428 | -- | 18.12 | -- | 49.23 | -- | -- | -- |
| Torrent Pharmaceuticals Ltd | 112.25bn | 18.02bn | 1.05tn | 14.92k | 58.25 | 13.99 | 40.37 | 9.35 | 53.25 | 53.25 | 331.63 | 221.72 | 0.7525 | 1.22 | 6.35 | 7,525,369.00 | 12.08 | 8.34 | 17.95 | 13.03 | 75.52 | 71.78 | 16.06 | 13.18 | 0.7444 | 9.32 | 0.2941 | 61.65 | 11.51 | 6.93 | 33.02 | 30.58 | -8.17 | 26.93 |
| Cipla Ltd | 265.12bn | 44.75bn | 1.18tn | 27.76k | 26.46 | 4.17 | 21.42 | 4.46 | 55.39 | 55.39 | 328.19 | 351.20 | 0.803 | 1.58 | 5.08 | 9,549,060.00 | 13.58 | 10.09 | 16.44 | 12.40 | 67.01 | 58.63 | 16.92 | 12.66 | 2.82 | 69.41 | 0.016 | 21.39 | 13.28 | 9.51 | 47.10 | 21.96 | 20.68 | 34.08 |
| Holder | Shares | % Held |
|---|---|---|
| Life Insurance Corporation of India (Investment Portfolio)as of 12 Jun 2024 | 41.85m | 5.02% |
| First Sentier Investors (Australia) IM Ltd.as of 31 Mar 2024 | 19.35m | 2.32% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 18.68m | 2.24% |
| ICICI Prudential Asset Management Co. Ltd.as of 31 Oct 2024 | 18.65m | 2.24% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 16.61m | 1.99% |
| SBI Funds Management Ltd.as of 31 Oct 2024 | 12.55m | 1.50% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Oct 2024 | 11.42m | 1.37% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Oct 2024 | 10.22m | 1.23% |
| APG Asset Management NVas of 31 Dec 2023 | 9.83m | 1.18% |
| Geode Capital Management LLCas of 14 Nov 2024 | 8.95m | 1.07% |
